Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026.
Recommended a final dividend of ₹2 per share (200%) for FY26, subject to shareholder approval.
Approved grant of 1,79,500 ESOPs at ₹784 per option and acquisition of MRI business from subsidiary for ~₹4.20 crore.
Noted Dr. D Nageshwar Reddy's decision not to seek reappointment as Independent Director from May 25, 2026.